Search | Clinical Trials Finder

Conditions: Healthy Volunteers
Interventions: Purified Inactivated Zika Virus Vaccine (PIZV), Placebo; Biological · Other
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 49 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 5
States / cities: Oakland Park, Florida • Meridian, Idaho • Wichita, Kansas + 2 more

Conditions: Hepatitis C Virus
Interventions: Sofosbuvir, Placebo to match sofosbuvir, PEG, RBV; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 22
States / cities: Montgomery, Alabama • Anaheim, California • Coronado, California + 17 more

Conditions: Schizophrenia
Interventions: Ralmitaront, Radiolabeled PET tracer [18F]-DOPA, Placebo; Drug · Other
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 4
States / cities: Glendale, California • Torrance, California • Gaithersburg, Maryland + 1 more

Conditions: Influenza A
Interventions: VIR-2482 (450 mg), VIR-2482 (1200 mg), Placebo; Biological
Lead sponsor: Vir Biotechnology, Inc.; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 2,977 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 51
States / cities: Anniston, Alabama • Mobile, Alabama • Tempe, Arizona + 45 more

Conditions: Multiple Myeloma
Interventions: BL-8040 1.25 mg/kg + G-CSF, Placebo +G-CSF; Drug
Lead sponsor: BioLineRx, Ltd.; Industry
Eligibility: 18 Years to 78 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2029
U.S. locations: 10
States / cities: Los Angeles, California • Gainesville, Florida • Miami, Florida + 7 more

Conditions: Overweight and Obesity
Interventions: Setmelanotide, Placebo; Drug
Lead sponsor: Rhythm Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 2
States / cities: Dallas, Texas • Madison, Wisconsin

Conditions: Type I Diabetes
Interventions: Exenatide (Bydureon®), Placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 8
States / cities: San Francisco, California • Aurora, Colorado • New Haven, Connecticut + 5 more

Conditions: HIV Infection
Interventions: PGT121 3mg/kg IV, PGT121 10mg/kg IV, PGT121 30mg/kg IV, PGT121 3mg/kg SC, Placebo (0.9% Sodium Chloride Injection USP (Saline)); Biological
Lead sponsor: International AIDS Vaccine Initiative; Network
Eligibility: 18 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Dengue
Interventions: TetraVax-DV Vaccine-Admixture 1, TetraVax-DV Vaccine-Admixture 2, TetraVax-DV Vaccine-Admixture 3, TetraVax-DV Vaccine-Admixture 4, Placebo, TetraVax-DV Vaccine-Admixture 5; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 141 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 4
States / cities: Washington D.C., District of Columbia • Baltimore, Maryland • Burlington, Vermont

Conditions: Type 2 Diabetes Mellitus, Chronic Kidney Disease, Left Ventricular Diastolic Dysfunction
Interventions: BYDUREON, Placebo; Drug
Lead sponsor: Baylor Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Clostridium Difficile Infection
Interventions: C. difficile Toxoid Vaccine, Placebo: 0.9% normal saline; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 50 Years and older
Enrollment: 9,302 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2018
U.S. locations: 142
States / cities: Huntsville, Alabama • Mobile, Alabama • Flagstaff, Arizona + 124 more

Conditions: Acute Renal Failure, Acute Kidney Injury
Interventions: I5NP, Placebo; Drug
Lead sponsor: Quark Pharmaceuticals; Industry
Eligibility: 21 Years to 85 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 10
States / cities: Birmingham, Alabama • Phoenix, Arizona • Washington D.C., District of Columbia + 5 more

Conditions: Muscular Dystrophies
Interventions: rAAV1.tMCK.human-alpha-sarcoglycan- First cohort, Genetic: rAAV1.tMCK.human-alpha-sarcoglycan- Second cohort; Genetic
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: 5 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Adhesive Capsulitis, Post-operative Pain
Interventions: Interscalene catheter with Ropivicaine or normal saline; Procedure
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: San Diego, California

Conditions: Immunoglobulin A Nephropathy (IgAN)
Interventions: ARGX-121, Placebo; Biological
Lead sponsor: argenx; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 9
States / cities: Valencia, California • Miami, Florida • Pembroke Pines, Florida + 4 more

Conditions: Rheumatoid Arthritis
Interventions: sarilumab SAR153191 (REGN88), tocilizumab, hydroxychloroquine, methotrexate, sulfasalazine, leflunomide, subcutaneous placebo, intravenous placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 14
States / cities: Huntsville, Alabama • Colorado Springs, Colorado • Aventura, Florida + 10 more

Conditions: Moderate-to-Severe Atopic Dermatitis
Interventions: Rezpegaldesleukin, Placebo; Drug
Lead sponsor: Nektar Therapeutics; Industry
Eligibility: 12 Years and older
Enrollment: 510 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 20
States / cities: Phoenix, Arizona • North Little Rock, Arkansas • Fountain Valley, California + 16 more

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Engensis, Placebo; Biological · Other
Lead sponsor: Helixmith Co., Ltd.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Hypertriglyceridemia
Interventions: Plozasiran Injection, Placebo; Drug
Lead sponsor: Arrowhead Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 1,456 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 97
States / cities: Birmingham, Alabama • Mobile, Alabama • Beverly Hills, California + 80 more

Conditions: Influenza
Interventions: Peramivir 150 mg, Peramivir 300 mg, Placebo; Drug
Lead sponsor: BioCryst Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 344 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 58
States / cities: Birmingham, Alabama • Jonesboro, Arkansas • Anaheim, California + 45 more

Conditions: Healthy Volunteers
Interventions: NoV Placebo-matching Saline, NoV GI.1/GII.4 Bivalent VLP Vaccine; Biological
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 4,748 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Great Lakes, Illinois

Conditions: Klinefelter Syndrome
Interventions: Testosterone Cypionate 200 Milligram/Milliliter Injectable Solution, Placebo injectable saline; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 31 Days to 90 Days · Male only
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Opioid-use Disorder, Chronic Pain Syndrome
Interventions: Naloxone Hydrochloride, Placebo; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: San Francisco, California

Conditions: HIV Infections
Interventions: DNA CON-S env, IHV01, Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: San Francisco, California

Search by objective public record fields.

A Study of Purified Inactivated Zika Virus Vaccine (PIZV) in Healthy Adults

Sofosbuvir in Combination With Pegylated Interferon and Ribavirin and in Treatment-Naive Hepatitis C-infected Patients

18F-Dihydroxyphenylalanine (DOPA) Positron Emission Tomography (PET) Study to Explore Dopamine Synthesis Capacity in the Whole Striatum After 2 Weeks of Treatment With Ralmitaront or Placebo in Participants With Schizophrenia

A Phase 2 Study to Evaluate the Efficacy and Safety of VIR-2482 for the Prevention of Illness Due to Influenza A

A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and Granulocyte Colony Stimulating Factor (G-CSF) as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Subjects With Multiple Myeloma (MM)

Phase 1b/2a Study to Evaluate Safety and Efficacy of Setmelanotide in Obese Patients

A Phase II Trial to Examine the Effect of Subcutaneous Exenatide (Bydureon®) on Glucose Control in Patients With Type I Diabetes

Safety, PK and Antiviral Activity of PGT121 Monoclonal Antibody in HIV-uninfected and HIV-infected Adults

Evaluation of the Safety and Immune Response of Five Admixtures of a Tetravalent Dengue Virus Vaccine

Extended Release Exenatide Versus Placebo In Diabetic Patients With Type 4 Cardiorenal Syndrome

Study of a Candidate Clostridium Difficile Toxoid Vaccine in Subjects at Risk for C. Difficile Infection

A Dose Escalation and Safety Study of I5NP to Prevent Acute Kidney Injury (AKI) in Patients at High Risk of AKI Undergoing Major Cardiovascular Surgery (QRK.004)

Gene Transfer Therapy for Treating Children and Adults With Limb Girdle Muscular Dystrophy Type 2D (LGMD2D)

Shoulder Adhesive Capsulitis and Ambulatory Continuous Interscalene Nerve Blocks

A Study to Evaluate the Effect of ARGX-121 on the Change in Proteinuria in Adult Participants With IgAN

To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN)

A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis

A 6-Month Extension Study to Assess the Long-Term Safety of Engensis in Amyotrophic Lateral Sclerosis

Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia

Evaluation of the Efficacy and Safety of Peramivir in Subjects With Uncomplicated Acute Influenza.

Efficacy and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-like Particle Vaccine in Adults

TESTO: Testosterone Effects on Short-Term Outcomes in Infants With XXY

The Effect of Chronic Pain on Delay Discounting in Methadone Patients

Evaluating the Safety and Immunogenicity of the IHV01 Protein Vaccine Primed and Co-Administered With HIV DNA CON-S Env Vaccine in Healthy, HIV-1-Uninfected Adults